Radioconjugates

Rising Interest in Radioconjugate Therapies

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Antibody-Drug Conjugates

Reducing ADC Development Timelines with Integrated Development and Manufacturing Services

Thomas Rohrer

Samsung Biologics

Biomanufacturing

New Name, Same Expertise: Goodwin Biotechnology is Becoming GBI!

Danielle Alvarez

Pharma's Almanac

Opioid Conjugate Vaccines

Vaccines Present a Novel Strategy for Opioid Overdose Prevention

Muctarr Sesay, Ph.D.

GBI

ADCS

Improving the Therapeutic Index of ADCs with a Peptide Linker Technology

Philipp Spycher

Araris Biotech AG

Antibody-Drug Conjugates

Accelerating ADC Development with Advanced Payload Intermediates

David Goeddel, Ph.D.

MilliporeSigma

Antibody–Drug Conjugates

Preparing for the ADC Explosion with End-to-End Support

Jyothi Swamy, Ph.D.; Elizabeth McKee

MilliporeSigma

Antibody–Drug Conjugates

Linking Novel Medicines to Patients with Hard-to-Treat Cancers for Improved Quality of Life

Loretta Itri, M.D., F.A.C.P.,; Usama Malik

Immunomedics

Antibody-Drug Conjugate

Fast-Tracking ADC Development and Commercialization

Matteo Piazza

PROVEO

Antibody-Drug Conjugate

Increasing the Potency of Antibody–Drug Conjugates

Philipp Spycher

Araris Biotech AG

FDA Approval

Genetech’s Antibody–Drug Conjugate Receives FDA Approval

Pharma's Almanac

ADC

Integrating ADC Manufacturing for the Future

Mark Frigerio, Ph.D.; Juan Carlos Cordova, Ph.D.

Abzena

ADC

Speeding up ADC Development With the Right Partner Organization

Courtney Morgret, Ph.D.

AbbVie Contract Manufacturing